This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Legangneux, E. Articles by Rosenzweig, P. Search for Related Content PubMed PubMed Citation Articles by Legangneux, E. Articles by Rosenzweig, P. Social Bookmarking                         What's this?

The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers

Synthelabo Recherche, Bagneux, France

J. McEwen

DDS Medicines Research Ltd, Ninewells Hospital and Medical School, Dundee, Scotland

K. A. Wesnes

Cognitive Drug Research Ltd, CDR House, Portman Road, RG30 1EA, UK; keithw{at}cdr.org.uk

L. Bergougnan

N. Miget

M. Canal

C. L'Heritier

J. L. Pinquier

P. Rosenzweig

Synthelabo Recherche, Bagneux, France

In this double-blind, placebo controlled, four-way cross-over trial in 16 healthy elderly volunteers, the acute effects of haloperidol 2 mg, amisulpride 50 mg and 200 mg, were assessed on a range of tests of cognitive function. On each study day, cognitive performance was assessed prior to dosing and at 2, 4, 6, 9, 12 and 24 h after dosing with the following tests from the Cognitive Drug Research computerized assessment system: simple reaction time, digit vigilance task, choice reaction time, visual tracking, Critical Flicker Fusion, body sway, numeric working memory, immediate and delayed word recall, word recognition and self-ratings of mood and alertness. Haloperidol showed a general tendency to impair performance, and although this did not reach significance compared to placebo, for two tasks there were significant impairments with haloperidol compared to amisulpride. Amisulpride 50 mg and 200 mg, was not associated with impairment. In fact, there was some suggestion of improvement over placebo on three measures. The timings of assessment were appropriate for the study compounds. Furthermore, in a recent study in which a smaller number of elderly volunteers was tested on the same cognitive assessment system, a clear profile of acute impairments of haloperidol 3 mg, was identified. This indicates that haloperidol 2 mg, is not a sufficient dose to affect cognitive function in the elderly, supporting the general absence of effects with this dose in the young. Thus, the general absence of cognitive impairments with amisulpride at the doses used in this study suggests that this compound does not impair cognitive function in the elderly.

Key Words: amisulpride • attention • computerized cognitive testing • haloperidol • secondary memory • working memory

Journal of Psychopharmacology, Vol. 14, No. 2, 164-171 (2000)
DOI: 10.1177/026988110001400206


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Liem-Moolenaar, F. Gray, S. de Visser, K. Franson, R. Schoemaker, J. Schmitt, A. Cohen, and J. van Gerven Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol J Psychopharmacol, January 1, 2010; 24(1): 73 - 82. [Abstract] [PDF]

				M. Muller, F. Eich, B Regenbogen, J Sachse, S Hartter, and C Hiemke Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder J Psychopharmacol, May 1, 2009; 23(3): 278 - 286. [Abstract] [PDF]

				M. Linden, T. Scheel, and F.-X. Eich Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride J Psychopharmacol, November 1, 2006; 20(6): 815 - 823. [Abstract] [PDF]